Biotechnology | Forum profile

>> gelded for... his orneriness << Good thing S.I. Bob is lenient!

Making Health Care Better........ Maybe a doctor that grew up on a small Idaho ranch has a solution to our medical system. This is an excellent article from today's NYT-Magazine. http://www.nytimes.com/2009/11/08/magazine/08Healthcare-t.html?_r=1&ref=magazine

At this point, the CEO's pride is potentially a real big negative. Didn't he say something like a $100m or $200m upfront like 2 years ago? If needed, can he swallow his pride and take a back loaded deal at this point with something "small" upfront? He won't sell the company around these prices. If he is not flexible with his deal making, he maybe is heading toward a bet with all his chips that the FDA will...

So out of curiosity I checked and it turns out I sortof-kinda have an Erdos number of 3 - in my student days I wrote a departmental working paper with someone who has an Erdos number of 2, although it was never actually externally published. So call it 3 with a couple of asterisks. :) But my best friend has a legitimate Erdos number of 2 about a dozen times over. Peter

Thanks Jason. I got spoiled by the Image Upload tool and completely forgot the proper format.

Mark, I don't disagree. I offered up $6 per share as a "point in time" price. End game could easily be >$60 per share.

That is why you... a) should have conference Calls quarterly to share what is going on b) You should publicize what you have to WALL STREET and not just the Science crowd c) You should enlist PROFESSIONALS to guide your firm through phases of the business you are not good at (PR). It shocks me on here that more support this company with their policy of not answering to shareholders. We have paid for their science experiments for over a...

(OT) The strangest thing I read this week... http://www.cabinetmagazine.org/issues/35/burnett_walter.php "...the authors set out to develop a means by which a given novel could express itself as a game of chess. Initial success here led to expanded ambition, since there was nothing to stop us from elaborating our modest analytic protocol into a full-fledged “engine” that would permit works of literature to confront one another on...

Please explain -- I missed the segue.

Ym Biosciences Reports Positive Nimotuzumab Four-Year Survival Data Presented at Astro 2009 - Follow-On Results from a Randomized Phase IIb Head & Neck Trial Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated Toxicities - MISSISSAUGA, ON, Nov. 2 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of...